The U.S. Food and Drug Administration has approved Datroway (datopotamab deruxtecan-dlnk) for adult patients with unresectable or metastatic, hormone receptor (HR)-positive, human epidermal growth ...
DATROWAY demonstrated statistically significant and clinically meaningful improvement in overall survival as 1st-line therapy for patients with metastatic triple-negative breast cancer for whom ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Patients with triple-negative breast cancer who were given the drug, Datroway, had a median overall survival of 23.7 months, compared with 18.7 months for those given just chemotherapy. Patients on ...
Datroway significantly improves overall and progression-free survival in metastatic triple-negative breast cancer patients ineligible for immunotherapy. TROPION-Breast02 trial results highlight ...
WILMINGTON, Del.--(BUSINESS WIRE)-- DATROWAY® (datopotamab deruxtecan-dlnk) has been approved in the US for the treatment of adult patients with locally advanced or metastatic EGFR-mutated non-small ...
What Is Datroway, and Why Does It Matter? Datroway (datopotamab deruxtecan-dlnk) is a prescription intravenous targeted cancer medicine called an antibody-drug conjugate (ADC). The FDA has approved it ...
Based on results from TROPION-Breast02, showing AstraZeneca and Daiichi Sankyo’s DATROWAY significantly improved overall survival vs. chemotherapy in this patient population If approved, DATROWAY ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results